Wuxi Zhikang Hongyi Biotechnology
Innovative oncology solutions with advanced WEE1 inhibitors for late-stage ovarian cancer treatment. Learn more
Launch date
Employees
Market cap
-
Enterprise valuation
CAD150—225m (Dealroom.co estimates Aug 2024.)
Jiangsu China (HQ)
Authorizing premium user...